Requirement of ATM-Dependent Phosphorylation of Brca1 in the DNA Damage Response to Double-Strand Breaks

American Association for the Advancement of Science (AAAS) - Tập 286 Số 5442 - Trang 1162-1166 - 1999
David Cortez1,2, Yi Wang3,2, Jun Qin3,2, Stephen J. Elledge4,1,2
1Howard Hughes Medical Institute
2Verna and Mars McLean Department of Biochemistry and Molecular Biology,
3Department of Cell Biology
4Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA

Tóm tắt

The Brca1 (breast cancer gene 1) tumor suppressor protein is phosphorylated in response to DNA damage. Results from this study indicate that the checkpoint protein kinase ATM (mutated in ataxia telangiectasia) was required for phosphorylation of Brca1 in response to ionizing radiation. ATM resides in a complex with Brca1 and phosphorylated Brca1 in vivo and in vitro in a region that contains clusters of serine-glutamine residues. Phosphorylation of this domain appears to be functionally important because a mutated Brca1 protein lacking two phosphorylation sites failed to rescue the radiation hypersensitivity of a Brca1-deficient cell line. Thus, phosphorylation of Brca1 by the checkpoint kinase ATM may be critical for proper responses to DNA double-strand breaks and may provide a molecular explanation for the role of ATM in breast cancer.

Từ khóa


Tài liệu tham khảo

10.1038/386761a0

10.1126/science.7792600

10.1016/S0165-4608(96)00328-7

10.1038/sj.bjc.6690460

10.1038/378789a0

10.1038/ng0396-333

10.1073/pnas.93.23.13084

10.1101/gad.10.19.2411

10.1038/ng1297-423

10.1101/gad.11.10.1242

10.1101/gad.11.10.1226

10.1016/S1097-2765(00)80035-0

10.1093/hmg/7.10.1555

10.1038/sj.onc.1202243

10.1038/386804a0

10.1016/S1097-2765(00)80466-9

; M. E. Maynahan J. W. Chiu B. H. Koler M. Jasin Mol. Cell in press.

10.1126/science.274.5293.1664

10.1126/science.281.5383.1677

10.1038/387516a0

10.1126/science.281.5383.1674

10.1126/science.282.5395.1893

10.1038/sj.onc.1202925

10.1016/S0960-9822(99)80041-4

10.1073/pnas.96.7.3745

10.1038/387520a0

10.1080/09553009114552601

10.2307/3578443

10.1080/095530097143266

10.1006/bbrc.1999.1024

10.1074/jbc.272.51.31941

10.1073/pnas.94.13.6927

10.1073/pnas.95.23.13869

10.1016/S0092-8674(00)81847-4

Chen J. J., Silver D., Cantor S., Livingston D. M., Scully R., Cancer Res. 59, 1752 (1999).

10.1016/S1097-2765(00)80276-2

10.1016/S0092-8674(00)80503-6

Vaughn J. P., et al., Cancer Res. 56, 4590 (1996);

Vaughn J. P., et al., Cell Growth Differ. 7, 711 (1996);

10.1006/dbio.1997.8526

10.1038/sj.onc.1201506

Chen Y., et al., Cancer Res. 56, 3168 (1996);

10.1073/pnas.94.14.7138

10.1128/MCB.19.7.4843

D. Cortez and S. J. Elledge unpublished data.

10.1074/jbc.274.26.18808

10.1073/pnas.94.11.5820

10.1038/38291

10.1101/gad.11.24.3471

Supplemental information is available at www.sciencemag.org/feature/data/1044763.shl.

10.1073/pnas.93.24.13595

10.1038/7684

10.1016/S0960-9822(07)00560-X

10.1073/pnas.90.18.8392

Tomlinson G. E., et al., Cancer Res. 58, 3237 (1998).

Goggins M., et al., Cancer Res. 56, 5360 (1996).

10.1038/sj.onc.1201319

GST-Brca1 expression vectors were constructed in pGEX2Tkcs or pGEX5X3 by polymerase chain reaction (PCR) with the following primers: pDC78 (Brca1 1 to 500) GAAAGCATATGATGGATTTATCTGCTCTTCGC and GAAAGCTCGAGTTAATTTGTGAGGGGACGCTC; pDC79 (Brca1 452 to 1079) GAAAGCATATGGTAGAGAGTAATATTGAAGAC and GAAAGCTCGAGCTATTTTGGCCCTCTGTTTCT; pDC80 (Brca1 1021 to 1552) GAAAGCATATGAGTACAGTGAGCACAATTAGC and GAAAGCTCGAGCTAGTAAGATGTTTCCGTCAA; pDC81 (Brca1 1501 to 1861) GAAAGCATATGTGCCCATCATTAGATGATAGG and GAAAGCTCGAGTCAGTAGTGGCTGTGGGGGAT; pDC113 (Brca1 1021 to 1211) GAAAGGATCCCAAGTACAGTGAGCACAATTAGCCG and GAAAGGTCGACGGACTCTAATTTCTTGGCCCCTC; pDC114 (Brca1 1211 to 1351) GAAAGGACCAGTCCTCAGAAGAGAACTTATCTAG and GAAAGGTCGACCAAGCCCGTTCCTCTTTCTTCATC; and pDC115 (Brca1 1351 to 1552) GAAAGGATCCGCTTGGAAGAAAATAATCAAGAAGA and GAAAGGTCGACGTAAGATGTTTCCGTCAAATCGTG. In vitro kinase assays were performed essentially as described (9). The ATM expression constructs were a kind gift of M. Kastan.

10.1021/ac971207m

10.1002/bms.1200160119

Single-letter abbreviations for the amino acid residues are as follows: A Ala; C Cys; D Asp; E Glu; F Phe; G Gly; H His; I Ile; K Lys; L Leu; M Met; N Asn; P Pro; Q Gln; R Arg; S Ser; T Thr; V Val; W Trp; and Y Tyr.

Flag-tagged NLS-Brca1 1351 to 1552 was constructed with the univector plasmid fusion system (29). The host vector is based on pCMV2-Flag (Sigma). The SV40 large T antigen NLS was inserted between the Hind III and Not I sites with the following primers: AGCTTCCCAAGAAGAAGAGGAAGGC and GGCCGCCTTCCTCTTCTTCTTGGGA. pUNI15 Brca1 1351 to 1552 was made with the same primers as those for pDC115 described above. The serine to alanine mutations were made by single-stranded mutagenesis with the following primers: S1423A ACAGCATGGGGCCCAGCCTTCTAACAG; and S1524A AAACTACCCAGCTCAAGAGGAACTCATTAAGGTTGTT. All mutations and PCR products were sequenced. Transfections were performed by standard calcium phosphate technique (30).

pBABEpuro HABrca1 was made by digesting pCDNA3βHABrca1 (16) with Sal I and Xho I and inserting it into the Sal I site of pBABEpuro. The serine to alanine mutations were inserted into wild-type Brca1 in pBABEpuro by exchanging a Pfl MI to Apa I Brca1 fragment from the mutated gene into pBABEpuro HABrca wild type. This deletes a portion of Brca1 because an Apa I site had been created by the introduction of the S1423A mutation. This deleted Brca1 segment was reintroduced as an Apa I to Apa I fragment derived from the full-length S1423A/S1524A mutant in pBSKII(−) reconstituting full-length HABrca1 S1423A/S1524A. Retrovirus was made by cotransfection of the pBABEpuro vectors with amphotrophic packaging DNA into 293T cells essentially as described (30). Viral supernatants were used to infect the HCC1937 cells. Two days after infection cells were selected for puromycin resistance with puromycin (1 μg/ml; Sigma).

We thank D. Livingston R. Scully M. Kastan and Y. Shiloh for providing reagents and M. Huang for helpful comments on the manuscript. D.C. is a Fellow of the Jane Coffin Childs Memorial Fund for Medical Research. This work was supported by grants GM44664 and Q1187 (Welch) to S.J.E. and grant IRG199A (American Cancer Society) and a grant from the L.E. Gordy Cancer Research Fund to J.Q. S.J.E is an Investigator with the Howard Hughes Medical Institute.